The XTEND Trial – Xpert for TB: Evaluating a New Diagnostic

In South Africa, the Department of Health is rolling out Xpert MTB/RIF, a new diagnostic test with improved sensitivity for detection of active TB combined with simultaneous detection of rifampicin resistance.

The XTEND study is a cluster randomised pragmatic trial ,where 20 laboratories in South Africa, in high burden TB districts are randomised to receive Xpert MTB/Rif technology, or not. The study will measure the effectiveness of Xpert MTB/RIF in improving patient and programme outcomes within this national roll-out.

 

tb-centre

 

Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF
Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant A, Fielding KL. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health. 2015 Aug 31;3(8):e450-7.

Back